Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Non-Hodgkin 11Lymphoma, B-Cell 9Hematologic Diseases 6Lymphoma, Mantle-Cell 5Leukemia, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Lymphoma 2Leukemia, Lymphoid 2Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1

Interventions

Cyclophosphamide 59fludarabine phosphate 42Peripheral Blood Stem Cell Transplantation 33Cyclosporine 32Busulfan 32Radiotherapy 30Mycophenolic Acid 30Filgrastim 30Antilymphocyte Serum 28Whole-Body Irradiation 26Melphalan 21Methylprednisolone 19Methotrexate 19Etoposide 19Tacrolimus 17Cord Blood Stem Cell Transplantation 17Cytarabine 10Thiotepa 9fludarabine 6aldesleukin 6sargramostim 5Vincristine 5Sirolimus 5Rituximab 5Psychiatric Rehabilitation 5Granulocyte Colony-Stimulating Factor 5Therapeutics 4Prednisone 4Doxorubicin 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × pirtobrutinib × Other hematologic neoplasm × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡